ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	16.41B -9.6%
Revenue (ttm)	3.16B -7.1%
Net Income	136.95M -59.6%
EPS	0.17 -60.4%
Shares Out	790.74M
PE Ratio	122.06
Forward PE	51.88
Dividend	0.35 (1.69%)
Ex-Dividend Date	Jul 3, 2025

Volume	885,175
Average Volume	1,586,625
Open	20.60
Previous Close	20.70
Day's Range	20.30 - 20.80
52-Week Range	16.25 - 29.10
Beta	0.58
RSI	43.05
Earnings Date	Feb 26, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CDMO services, such as contract analytical testing services, s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.